Investor Presentaiton
16
Clinical Development Strategy for INO-4800
☐ US - Phase 1 study of INO-4800 under US IND
Initial funding of up to $9M awarded by CEPI
Rapid start of FIH study in young, healthy population; expanded in older adults
Preliminary safety and robust immune response data announced in late June
☐ Ex-US Studies in China and Korea
☐
Collaborations formed between INOVIO and Advaccine in China, as well as IVI in Korea to
build global consortium for joint clinical development
$7.3 million from CEPI to support the Korea Phase 1/2a trial initiated in June 2020
☐
Phase 1 study in China also initiated
☐ Phase 2/3 Efficacy Study in the US
☐
Study protocol being developed to assess the efficacy for prevention of COVID-19 in
high-risk population
Expected to start in September pending regulatory approval
INOVIO
POWERING DNA MEDICINESView entire presentation